SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more
SynCore Biotechnology Co Ltd - Asset Resilience Ratio
SynCore Biotechnology Co Ltd (4192) has an Asset Resilience Ratio of 2.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how SynCore Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down SynCore Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$7.04 Million | 2.58% |
| Total Liquid Assets | NT$7.04 Million | 2.58% |
Asset Resilience Insights
- Limited Liquidity: SynCore Biotechnology Co Ltd maintains only 2.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SynCore Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare SynCore Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for SynCore Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.19% | NT$6.96 Million | NT$317.80 Million | +0.43pp |
| 2023-12-31 | 1.76% | NT$6.66 Million | NT$378.36 Million | +0.23pp |
| 2022-12-31 | 1.53% | NT$6.66 Million | NT$436.65 Million | +0.72pp |
| 2021-12-31 | 0.81% | NT$6.66 Million | NT$824.44 Million | +0.08pp |
| 2020-12-31 | 0.73% | NT$6.66 Million | NT$913.99 Million | -0.14pp |
| 2019-12-31 | 0.87% | NT$6.66 Million | NT$763.88 Million | +0.04pp |
| 2018-12-31 | 0.83% | NT$6.66 Million | NT$804.80 Million | +0.04pp |
| 2017-12-31 | 0.79% | NT$6.66 Million | NT$845.89 Million | +0.19pp |
| 2016-12-31 | 0.60% | NT$6.66 Million | NT$1.11 Billion | -0.05pp |
| 2015-12-31 | 0.65% | NT$6.63 Million | NT$1.03 Billion | -- |